Czechia· CZ-0186994

ELOCTA

A coagulation factor viii product containing efmoroctocog alfa, registered in Czechia by Swedish Orphan Biovitrum AB (publ), Stockholm. The same ATC class is registered in 11 of our 19 countries.

ATC B02BD02

Checked against SÚKL (Czech Republic) on

Informational only — not a medical device.

SOURCE REGISTER · CZSÚKL (Czech Republic)normalisedELOCTAATCB02BD02REGISTER NO.CZ-0186994PACKS LISTED1CHECKEDSeptember 28, 2026

Where it is registered

Coagulation factor viii is registered in 11 of 19 countries.

Countries holding a registration under ATC B02BD02 (coagulation factor viii), each read from that country’s own register.

  • This record: Czechia, from SÚKL (Czech Republic)
  • 7 of them publish a price we can compare per daily dose

Coagulation factor viii · ATC B02BD02

11 / 19 countries

  • Belgiumprice
  • Canada
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Icelandprice
  • Ireland
  • Netherlands
  • Norwayprice
  • Polandprice
  • Switzerlandprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

The record

At a glance

SÚKL (Czech Republic)
Active substance
EFMOROCTOCOG ALFA
Manufacturer
Swedish Orphan Biovitrum AB (publ), Stockholm
Country
Czechia (CZ)
ATC code
B02BD02
ATC class
Coagulation factor VIII
Defined daily dose
1 TSD, E
Reimbursed
Not published by this register
Source register
SÚKL (Czech Republic)
Last checked
September 28, 2026

Packs & prices · 1

1 priced
  • cz_kod_sukl
    0186994
    1+1X3ML ISP+AD
    CZK 22978.95

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

4 interactions on record for coagulation factor viii.

Graded by severity as the source publishes them — 2 severe. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan

Coagulation factor viii · interactions on record

4 records

  • 2 severe
  • 2 moderate

Most severe, free to view

  • CarfilzomibL01XG02severe
  • CarfilzomibL01XX45severe
  • PegvaliaseA16AB19moderate
  • EmicizumabB02BX06moderate
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of SÚKL (Czech Republic). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/d41624e8-5f5f-4ca2-9909-a7ca15f53f6f
GET /v1/drugs/d41624e8-5f5f-4ca2-9909-a7ca15f53f6f?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "INJ PSO LQF",
  "source": "sukl",
  "strength": "750IU",
  "pack_size": "1+1X3ML ISP+AD",
  "substance": "EFMOROCTOCOG ALFA",
  "cz_kod_sukl": "0186994",
  "product_type": "BT",
  "substance_codes": "20511",
  "registration_state": "R",
  "registration_number": "EU/1/15/1046/003"
}

See everything about coagulation factor viii.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.